Impact Biomedicines, Inc.

Impact Biomedicines, Inc. is a biotechnology company focused on developing innovative therapies for serious diseases, particularly in the field of oncology. It aims to revolutionize treatment options through advanced biopharmaceutical research. Founded in 2016 and headquartered in San Diego, US, Impact Biomedicines, Inc.

specializes in developing biopharmaceuticals. In January 2018, Celgene entered into a definitive agreement to acquire the company for USD 1100 mn, potentially rising to USD 7000 mn based on regulatory milestones and sales performance. Impact Biomedicines, Inc. is part of Bristol Myers Squibb, a global biopharmaceutical company dedicated to discovering, developing, and delivering medications for serious diseases.

Their product portfolio includes significant therapies such as Opdivo (nivolumab) and Yervoy (ipilimumab), which target cancer through immune system mechanisms, with a broad customer base across North America, Europe, and Asia-Pacific regions. Bristol Myers Squibb generates revenue primarily through direct sales to healthcare providers and partnerships with pharmaceutical retailers. Their revenue structure is based on proprietary product sales, including flagship medications that are purchased by healthcare institutions under established pricing agreements. Collaborative partnerships further enhance revenue streams, ensuring financial stability and growth.

Following the most recent deal in January 2018, which involves a strategic acquisition by Celgene, Impact Biomedicines, Inc. is poised to enhance its product offerings and expand its market presence. The company plans to utilize the USD 1100 mn from this acquisition to support the development of new therapies and potentially enter untapped markets in Europe and Asia by 2020.